Substituted Quinazolines as Inhibitors of Kras G12C
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 62/052,366, filed Sep 18, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,840,516 | Substituted Quinazolines as Inhibitors of Kras G12C In force · High confidence UsedRemaining | Araxes Pharma LLC | In force | High confidence | ||
| US 10,370,386 | Substituted Quinolines as Inhibitors of Kras G12C In force · High confidence | Araxes Pharma LLC | In force | High confidence | ||
| US 10,927,125 | Substituted Cinnolines as Inhibitors of Kras G12C In force · High confidence | Araxes Pharma LLC | In force | High confidence | ||
| US 11,878,985 | Substituted Quinazolines as Inhibitors of Kras G12C In force · High confidence | Araxes Pharma LLC | In force | High confidence | ||
| US 12,234,244 | Substituted Piperazines as Inhibitors of Kras G12C In force · High confidence | Araxes Pharma LLC | In force | High confidence | ||
| Application 18/178,452 | Substituted Piperazines as Inhibitors of Kras G12C Abandoned Abandoned Jul 1, 2024 | Araxes Pharma LLC | Abandoned | Abandoned Jul 1, 2024 | ||
| Application 18/183,870 | Substituted Piperazines as Inhibitors of Kras G12C Abandoned Abandoned Jul 1, 2024 | Araxes Pharma LLC | Abandoned | Abandoned Jul 1, 2024 | ||
| Application 18/416,739 | Substituted Piperazines as Inhibitors of Kras G12C Pending Not granted | Araxes Pharma LLC | Pending | Not granted |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Araxes Pharma LLC.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.